The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
DSP-0390, an oral emopamil binding protein (EBP) inhibitor, in patients with recurrent high-grade glioma: A first-in-human, phase 1 study.
 
David A. Reardon
Honoraria - Advantagene; Agenus; Anheart Therapeutics; Bayer; Bristol-Myers Squibb; Deciphera; DelMar Pharmaceuticals; Ellipses Pharma; EMD Serono; Genenta Science; Imvax; Inovio Pharmaceuticals; Kintara Therapeutics; Kintara Therapeutics; KIYATEC; Medicenna; Merck; Merck KGaA; NEUVOGEN; Novocure; Oncorus; Regeneron; Sumitono Dainippon Pharma; Taiho Pharmaceutical; Taiho Pharmaceutical; Vivacitas Oncology; Y-mAbs Therapeutics
Consulting or Advisory Role - Advantagene; Agenus; Agios; Anheart Therapeutics; Bayer; Bristol-Myers Squibb; Delmar Pharmaceuticals; Ellipses Pharma; EMD Serono; Genenta Science; Imvax; Kintara Therapeutics; Kiyatec; Medicenna; Merck; Merck KGaA; Novocure; Oncorus; Regeneron; Taiho Pharmaceutical; Vivacitas Oncology
Research Funding - Acerta Pharma (Inst); Agenus (Inst); Celldex (Inst); EMD Serono (Inst); Enterome (Inst); Incyte (Inst); Omniox
 
Yoshitaka Narita
Honoraria - Chugai Pharma; Daiichi Sankyo; Eisai; Novocure; Ono Pharmaceutical
Consulting or Advisory Role - Dainippon Sumitomo Pharma
Research Funding - Daiichi Sankyo (Inst); Dainippon Sumitomo Pharma (Inst); Eisai (Inst); Ohara Pharmaceutical (Inst); Ono Pharmaceutical (Inst); Stella pharma (Inst); Taiho Pharmaceutical (Inst)
 
Yoshiki Arakawa
Speakers' Bureau - Brainlab; Chugai Pharma; Daiichi Sankyo; Eisai; Merck; Nihon Medi-Physics; Nippon Kayaku; Novocure; Ono Pharmaceutical; UCB; Zeiss
Research Funding - Chugai Pharma (Inst); Daiichi Sankyo (Inst); Eisai (Inst); Japan Blood Products Organization (Inst); Nihon Medi-Physics (Inst); Nihon Medi-Physics (Inst); Ono Pharmaceutical (Inst); Otsuka (I); Philips Healthcare (Inst); Siemens (Inst); Stryker (Inst); Sumitomo Dainippon Pharma (Inst); Taiho Pharmaceutical (Inst)
 
Samuel A. Goldlust
Employment - Regional Cancer Care Associates
Leadership - Cellevolve
Stock and Other Ownership Interests - COTA
Honoraria - Cornerstone Specialty Network; Daiichi Sankyo/Astra Zeneca; Physicans' Education Resource
Consulting or Advisory Role - Boston Biomedical; Cellevolve; Novocure; Sumitomo Dainippon Pharma Oncology
Speakers' Bureau - Novocure
Research Funding - Abbvie (Inst); Acerta Pharma (Inst); Amgen (Inst); Boehringer Ingelheim (Inst); Boston Biomedical (Inst); Bristol-Myers Squibb (Inst); Cantex Pharmaceuticals (Inst); Celgene (Inst); Celldex (Inst); Celularity (Inst); CNS Healthcare (Inst); Cortice Biosciences (Inst); Diffusion Pharmaceuticals (Inst); ImmunoCellular Therapeutics (Inst); Imvax (Inst); Imvax (Inst); Karyopharm Therapeutics (Inst); Kazia Therapeutics (Inst); Merck (Inst); Northwest Biotherapeutics (Inst); Novocure (Inst); Novogen (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); Regeneron (Inst); Sanofi (Inst); Sumitomo Dainippon Pharma Oncology (Inst); Tocagen (Inst); Wex Pharmaceuticals (Inst)
Travel, Accommodations, Expenses - Caris Life Sciences; Kyowa Kirin International; Novocure
 
George Ansstas
Consulting or Advisory Role - Novartis
Research Funding - Novocure
 
Jian Mei
Employment - Sumitomo Dainippon Pharma
 
Edward Dow
Employment - Sumitomo Dainippon Pharma
 
Masataka Seki
No Relationships to Disclose
 
Yudai Furuta
Employment - Sumitomo Dainippon Pharma
 
Gregory Song
Employment - Sumitomo Dainippon Pharma
 
Howard Colman
Consulting or Advisory Role - Abbvie; Adastra Pharmaceuticals; Adastra Pharmaceuticals; Bayer; Best Doctors, Inc; FORMA Therapeutics; Karyopharm Therapeutics; Newlink Genetics; Orbus Therapeutics; Private Health
Research Funding - Abbvie (Inst); Array BioPharma (Inst); Bayer; BeiGene (Inst); Bristol-Myers Squibb; DNAtrix (Inst); FORMA Therapeutics (Inst); Global Coalition for Adaptive Research (Inst); Kadmon (Inst); Merck (Inst); Newlink Genetics (Inst); Nuvation Bio; Orbus Therapeutics (Inst); Plexxikon (Inst)
Travel, Accommodations, Expenses - Bayer; FORMA Therapeutics; Karyopharm Therapeutics; Orbus Therapeutics